The expressed hIL22RA is thought to heterodimerize with endogenous IL10RB (IL10 receptor subunit beta), and this complex senses the presence of IL22, driving expression of output molecules to treat psoriasis, IL4 and IL10, via STAT3 (signal transducer and activator of transcription 3) signaling. Here, IL22 is linked to psoriasis.